Cancer Therapy AdvisorASCO 2026 Late Breakers: What We’re Watching and What It Means

🎓 Expert Commentary / Peer Perspective

A community oncology podcast preview highlighted four ASCO 2026 late-breaking trials: RASolute 302 (daraxonrasib in RAS-driven pancreatic adenocarcinoma), PROTEUS (perioperative intensification in high-risk localized prostate cancer), LIBRETTO-432 (adjuvant selpercatinib in RET-fusion NSCLC), and SARC041 (abemaciclib in dedifferentiated liposarcoma).

Clinical Considerations

• RASolute 302 offers a potential oral second-line option in pancreatic cancer, with attention warranted to ocular toxicities requiring ophthalmology coordination
• PROTEUS tests whether neoadjuvant systemic therapy and pathologic response assessment can translate from breast and rectal cancer into prostate, where urologic-first referral patterns dominate
• LIBRETTO-432 would move selpercatinib from metastatic into curative-intent adjuvant use, reinforcing the case for comprehensive molecular testing at diagnosis rather than at recurrence
• SARC041 evaluates biomarker-driven drug repurposing, examining CDK4-overexpressing dedifferentiated liposarcoma response to a drug class clinicians associate with breast cancer

Practice Applications

• Anticipate infrastructure demands for molecular testing workflows if adjuvant targeted therapy expands
• Recognize ocular toxicity management needs when novel RAS inhibitors enter community practice
• Integrate multidisciplinary referral pathways early when neoadjuvant paradigms cross into urology-led tumor types
• Interpret these previews as anticipatory framing pending presented data and peer review